Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.50 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.47 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 7/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 7/20 | 0.43 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL496040 | 0.98 | HDAC8 (0.51) | HDAC8CSNK1ECARM1MEN1KMT2A | |
| SCHEMBL496381 | 0.90 | PRMT5 (0.56) | HDAC8CARM1PRMT5WDR77 | |
| Hydrochloric Acid SCHEMBL495605 | 0.89 | PRMT5 (0.55) | HDAC8CARM1PRMT5WDR77 | |
| SCHEMBL12635744 | 0.85 | CSNK1E (0.43) | HDAC8CSNK1ECARM1MEN1KMT2A | |
| SCHEMBL12635740 | 0.85 | CSNK1E (0.43) | HDAC8CSNK1ECARM1MEN1KMT2A | |
| SCHEMBL12635754 | 0.85 | HDAC8 (0.43) | HDAC8CSNK1EPRMT5WDR77 | |
| SCHEMBL4730009 | 0.83 | EPHX1 (0.55) | HDAC8CARM1MEN1KMT2AEPHX1 | |
| SCHEMBL495874 | 0.83 | CSNK1E (0.48) | CSNK1EMEN1KMT2AEPHX1SLC15A1 | |
| Hydrochloric Acid SCHEMBL496018 | 0.81 | CSNK1E (0.47) | CSNK1EMEN1KMT2AEPHX1SLC15A1 | |
| SCHEMBL496919 | 0.81 | TSHR (0.47) | CSNK1EMEN1KMT2AEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910317-B1 | 1-AMINO LINKED COMPOUNDS | LILLY CO ELI (US) | 2013-07-03 | — | — | EP | disclosed |
| EP-1910317-B1 | 1-AMINO LINKED COMPOUNDS | LILLY CO ELI (US) | 2013-07-03 | — | — | EP | disclosed |
| US-8106090-B2 | Antidiabetic agents; prevent of non-insulin dependent diabetes | ELI LILLY AND COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106090-B2 | Antidiabetic agents; prevent of non-insulin dependent diabetes | ELI LILLY AND COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106090-B2 | Antidiabetic agents; prevent of non-insulin dependent diabetes | ELI LILLY AND COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| US-20080207735-A1 | 1-Amino Linked Compounds | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
| US-20080207735-A1 | 1-Amino Linked Compounds | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
| US-20080207735-A1 | 1-Amino Linked Compounds | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
| EP-1910317-A1 | 1-AMINO LINKED COMPOUNDS | Eli Lilly and Company (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007015805-A1 | 1-AMINO LINKED COMPOUNDS | ELI LILLY AND COMPANY (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207735-A1 | 1-Amino Linked Compounds | DPP4, DPP3, DPP9 | HDAC8 1464/4885CSNK1E 194/4885CARM1 1191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.